# ZYNRELEF

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/zynrelef
Canonical HTML page: https://getyourbrief.com/entity/zynrelef

## Recent coverage (2 stories, network-wide)

### Mid-Cap Biotech Resilience: Lantheus and Heron Navigate Mixed Q4 Results
2026-02-26 13:18:52 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
Full story: https://getfinancebrief.com/story/lantheus-heron-q4-earnings-fy26-outlook

### Q4 2025 Biotech Earnings: Delcath and Peers Face Critical Commercial Milestones
2026-02-25 15:07:22 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Full story: https://getbiobrief.com/story/biotech-pharma-q4-2025-earnings-preview-delcath-lantheus

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.